After positive phase 2b data, narcolepsy agent TAK-861 moves on to phase 3 studies.

Published Date: 15 Feb 2024

In a phase 2b trial for narcolepsy type 1, the orexin receptor 2 agonist TAK-861 showed efficacy and safety.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Studies have shown that physical activity prevents cancer in patients who have been treated for cancer in the past.

2.

Glioblastoma treatment breakthrough shows promise

3.

Expert Q&A: A Drug Holiday for Metastatic Prostate Cancer?

4.

Marstacimab Gets FDA Nod for Hemophilia A or B Without Inhibitors

5.

Small-Town Patients Face Big Hurdles as Rural Hospitals Cut Cancer Care


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot